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Abstract Introduction. The latest histological classification of lung adenocarcinoma includes lepidic, 
acinar, papillary, micropapillary, and solid as subtypes. Testing these subtypes for their 
prognostic and predictive value is an ongoing scientific challenge. The present research article 
aims to describe the influence this classification has on patient survival.  
Materials and Methods.  Thirty-three patients were included in the trial. The most important 
enrollment criterion was the clear specification of the adenocarcinoma subtype in the pathology 
report. Patients were stratified into three groups which included the adenocarcinoma pathological 
subtypes as follows: lepidic (LEP), acinar and papillary (ACN/PAP), and micropapillary/solid 
(MIP/SOL). The primary endpoint was progression-free survival. Other endpoints included 
overall survival. 
Results. The lepidic subtype of ADC had superior PFS and OS, regardless of stage. Papillary 
and acinar subtype showed an intermediate prognosis, whereas micropapillary and solid subtypes 
were the most aggressive. 
Conclusions. The experience of this single center confirmed data in the literature. Further 
studies are needed to demonstrate all the possible implications of this pathology classification.     
  












Highlights ✓ The standardization of pathological assessment in lung ADC is essential for both early 
and advanced stages.  
✓ The lepidic subtype of ADC carries the best prognosis for PFS and OS, whereas 





Lung cancer is currently the most frequent 
neoplastic disease. Even if measures to reduce smoking 
in the population have succeeded in lowering the rate of 
lung squamous carcinoma, the incidence of lung 
adenocarcinoma (ADC) is rising (1). As opposed to 
breast and prostate cancer, where pathological subtypes 
and tumour grading influence both prognosis and 
treatment decisions, ADC of the lung had no 
standardized pathological classification until recently, 
so cancers were frequently reported as mixed 
histologies. For many years, it was considered that lung 
ADC was histologically too heterogeneous to permit 
classifying. Most of the samples have components of all 
types, with one being predominant. Bronchioloalveolar 
carcinoma is the exception to this paradigm, being well 
known to be a pure lepidic tumour.   
In 2011, as the International Association for the 
Study of Lung Cancer (IASLC) and the American 
Thoracic Society (ATS) issued a novel classification of 
lung ADC, a search for prognostic significance began. 
ADC was then classified as lepidic (LEP), acinar 
(ACN), papillary (PAP), micropapillary (MIP), and 
solid (SOL). These subtypes are the foundation of the 
new WHO classification system of lung ADC based 
mainly on tumour architecture (2). Some histological 
subtypes of lung ADC (stage I) benefit more from 
adjuvant treatment, as recent publications have 
demonstrated (3). The prognostic implications in more 
advanced stages have yet to be demonstrated. The 
present trial is meant to illustrate the experience of a 
single institution on this matter. 
Materials and Methods 
Thirty-three patients were enrolled in this 
prospective, observational trial. The patients were 
treated in only one center, Elias University Emergency 
Hospital, Clinic of Oncology, Bucharest. Enrollment 
began in 2015 and inclusion criteria included: diagnosis 
of lung adenocarcinoma, stages I-III, and treated with 
surgery/ chemotherapy/ radiochemotherapy in any 
combination. The most important enrollment criterion 
was the clear specification of the adenocarcinoma 
subtype in the pathology report. No ’mixed’ histologies 
were included, even if they specified one predominance. 
Patients were stratified into three groups which included 
the following pathological subtypes of adenocarcinoma: 
lepidic (LEP), acinar and papillary (ACN/PAP), and 
micropapillary/solid (MIP/SOL). These associations 
were made because some of them included too few 
patients for clinical significance. All patients were 
followed from diagnosis until death for any cause. If 
death did not occur by the end of follow-up, the patients 
were censored.  
The primary endpoint was progression-free 
survival, with a secondary endpoint of overall survival. 
Follow-up was represented graphically using the Kaplan 
Meier curve. Statistical analysis was processed using 
SPSS Statistics version 20. 
Results 
Of the total number of patients (n=33), 27,3% (n=9) 
were stage I, 30,3% (n=10) stage II, and 42,2% (n=14) 
stage III. Nodal involvement was distributed as follows: 
N1- 30,3%, N2- 27.3%, and N3- 12.1%. Mean age at 
diagnosis was 59.8 years with a maximum of 78 and a 
minimum of 73, standard deviation 9,78.  
51.5% (n=16) of patients underwent pneumectomy 
and 48.5% (n=16) less extensive surgery. The frequency 
of the pathological subtypes were: LEP-12.1%  (n=4), 
ACN/PAP -63.6% (n=21), MIP/SOL- 24.2% (n=8). 
84.8% (n=28) were assigned to some type of adjuvant 
treatment (Table 1). 
Table 1. Clinical and demographic characteristics 
of patients 





Male 1 11 6 
Female 3 10 2 
Stage (TNM)    
I 2 5 2 
II 1 7 2 
III 1 9 4 
N stage    
0 2 5 3 
1 1 8 1 
2 1 6 0 
3 0 2 2 
T stage    
1 2 4 1 
2 1 7 4 
3 1 10 3 
Type of 
surgery 
   
Pneumoectomy 2 12 3 
Other 2 9 5 
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The rate of recurrence for stage I and II was 45% 
during the 41 months of follow-up.  
Progression-free survival (PFS) in the three 
adenocarcinoma subtype groups is represented in Figure 
2. Mean time to progression in the LEP group was 34.3 
months, whereas in the ACN/PAP and MIP/SOL 
subgroups, the mean time was 17.6 months and 8.3 
months respectively. Log Rank (Mantel-Cox) test value 
was 11.5, p=.003.     
 
Figure 1. Kaplan Meier curve for 
progression-free survival in the three 
subgroups (LEP, ACN/PAP, MIP/SOL)  
Overall survival for the same three subgroups is 
represented in Figure 2. Mean survival time in the LEP 
group was 29 months, 29 months in the ACN/PAP 
group, and 17.5 months in the MIP/SOL group. Log 
Rank (Mantel-Cox) test value was 2.51, p=.285. 
 
Figure 2. Kaplan Meier curve for overall 
survival for the LEP, ACN/PAP and 
MIP/SOL subtypes 
PFS was then stratified for each stage for the three 




Figure 3. Kaplan Meier curve for PFS for 
the LEP, ACN/PAP and MIP/SOL 





In the present trial, most patients were stage II, and 
the most frequent nodal involvement was N2. The most 
frequent pathological subtypes were ACN/PAP, which 
is consistent with recent literature data (4). The LEP 
subgroup had clear PFS advantage, followed by 
ACN/PAP subgroup. The reason this trial was designed 
with PFS as the primary endpoint instead of OS is the 
relatively short time of follow up (maximum 41 
months). Therefore, the present data can be considered 
a preliminary analysis, as patients will continue to be 
followed. One of the weak points of this analysis is the 
small number of enrolled patients and the small 
proportion of patients with lepidic ADC (only 4). 
Because of these small subgroups, some analyses, for 
example, PFS in stage II patients, cannot be considered 
reliable.     
Another consideration is the lack of standardization 
in pathological assessment, done by more than one 
observer in 3 centers of Pathology. WHO recommends 
that the entire sample should be fragmented in parts of 
5%, so as to establish a predominant pathological 
subtype. In our trial, the most suggestive sample of the 
resected/ biopsied specimen was selected and analyzed 
(2, 5). 
The superiority of progression free survival and 
overall survival in the lepidic subtypes has also been 
confirmed in larger trials (6). 
The classification system has proved its utility in 
treatment decisions as well, especially for early-stage 
lung cancer. A clinical trial by Tsao et al. was the first 
to demonstrate that MIP/SOL histology early stage lung 
ADC benefits most from adjuvant chemotherapy. This 
trial, which included 575 patients, demonstrated PFS 
and disease-related PFS benefit in the lepidic subgroup, 
but failed to prove benefit on OS (7).       
In our trial, the superiority of survival in the lepidic 
subgroup was also statistically non-significant. 
Variation among observers/assessors is an issue that was 
addressed in the consensus that issued the novel 
classification, and data in the literature demonstrated 
that the most concordant results are ones describing the 
solid subtype. It seems that this subtype is the easiest to 
recognize. The experience of the observer is also 
paramount, and pathological assessment should be done 
in a specialized center. In our trial, all three centers that 
provided pathological analyses are high volume ones (8, 
9). 
The recurrence rate reported for the early stage of 
lung ADC is 50%, consistent with the findings of the 
present trial. Given this high rate of recurrence, the 
necessity for prognostic and predictive biomarkers has 
emerged. Several molecular biomarkers (like ERCC1 or 
KRAS) have been studied in an attempt to establish 
which subtypes benefited most from adjuvant 
chemotherapy, but studies have not provided consistent 
evidence (10). Therefore, the data presented in the Tsao 
trial is important (7).      
A question that still needs to be addressed is the 
prognostic significance of the papillary subtype.  Trials 
that have focused on this issue have yielded different 
results. In the Australian population, for example, better 
survival was reported in the papillary subgroup, 
compared to the micropapillary or the solid ones (10, 
11). But results were different in the Japanese 
population, with a study reporting similar outcomes in 
all three subtypes (12, 13). One exciting hypothesis 
implies that early stage papillary ADC has a different 
prognosis in radiochemotherapy-treated patients 
compared with chemotherapy-only patients. Whether 
this subtype is more sensitive to combined therapeutical 
modalities awaits further study (14).  
The prognostic implication of the minority 
component of the tumour is still a topic for debate. 
Several attempts related to this minority component 
have been made, yet possible correlations regarding 
survival or other endpoints are still unclear (3). 
However, some trials suggest that the non-lepidic 
component of an early stage tumour is the only one that 
carries prognostic significance. A bold proposal was to 
insert this information in the T stage of the TNM system, 
but stronger statistical support is needed (11).      
Conclusions 
To summarize, the lepidic subtype of ADC carries 
the best prognosis for PFS and OS, regardless of stage. 
Papillary and acinar subtypes carry an intermediate 
prognosis, whereas micropapillary and solid subtypes 
are considered the most aggressive. The standardization 
of pathological assessment in lung ADC is essential for 
both early and advanced stages. Further studies are 
needed to demonstrate the many possible implications 
of this histological classification.  
Can non-small cell lung cancer predict survival? 
259 
 
Conflict of interest disclosure 
There are no known conflicts of interest in the 
publication of this article, and there was no financial 
support that could have influenced the outcomes. The 
manuscript was read and approved by all authors. 
Compliance with ethical standards 
Any aspect of the work covered in this manuscript 
that has involved human patients has been conducted 
with the ethical approval of all relevant bodies and that 
such approvals are acknowledged within the manuscript. 
Acknowledgments 
All authors contributed equally to this research.  
References 
1. Sun S, Schiller JH, Gazdar AF. Lung cancer in 
never smokers—a different disease. Nat Rev 
Cancer. 2007; 7(10): 778–90. DOI: 
10.1038/nrc2190        
2. Travis WD, Brambilla E, Noguchi M, et al. 
International Association for the Study of Lung 
Cancer/American Thoracic Society/European 
Respiratory Society international multidisciplinary 
classification of lung adenocarcinoma. J Thorac 
Oncol. 2011; 6(2): 244-85.  
DOI: 10.1097/JTO.0b013e318206a221     
3. Sica G, Yoshizawa A, Sima CS, et al. A grading 
system of lung adenocarcinomas based on 
histologic pattern is predictive of disease recurrence 
in stage I tumors. Am J Surg Pathol. 2010; 34(8): 
1155-62. DOI: 10.1097/PAS.0b013e3181e4ee32       
4. Motoi N, Szoke J, Riely GJ, et al. Lung 
adenocarcinoma: Modification of the 2004 WHO 
mixed subtype to include the major histologic 
subtype suggests correlations between papillary and 
micropapillary adenocarcinoma subtypes, EGFR 
mutations and gene expression analysis. Am J Surg 
Pathol. 2008; 32(6): 810-27.  
DOI: 10.1097/PAS.0b013e31815cb162 
5. Travis WD, Brambilla E, Nicholson AG, et al. The 
2015 World Health Organization Classification of 
Lung Tumours: impact of genetic, clinical  
and radiologic advances since the 2004 
classification. J Thor Oncol. 2015; 10(9): 1243–60. 
DOI: 10.1097/JTO.0000000000000630      
6. Warth A, Muley T, Meister M, Stenzinger A, 
Thomas M, Schirmacher P, Schnabel PA, Budczies 
J, Hoffmann H, Weichert W. The Novel Histologic 
International Association for the Study of Lung 
Cancer/American Thoracic Society/European 
Respiratory Society Classification System of Lung 
Adenocarcinoma Is a Stage-Independent Predictor 
of Survival, J Clin Oncol. 2012; 30(13): 1438-46. 
DOI: 10.1200/JCO.2011.37.2185 
7. Tsao MS, Marguet S, Le Teuff G, Lantuejoul S, 
Shepherd FA, Seymour L, Kratzke R, Graziano SL, 
Popper HH, Rosell R, Douillard JY, Le-Chevalier 
T, Pignon JP, Soria JC, Brambilla EM2. Subtype 
Classification of Lung Adenocarcinoma Predicts 
Benefit from Adjuvant Chemotherapy in Patients 
Undergoing Complete Resection. J Clin Oncol. 
2015; 33(30): 3439-46.  
DOI: 10.1200/JCO.2014.58.8335    
8. Warth A, Stenzinger A, von Brünneck AC, et al. 
Interobserver variability in the application of the 
novel IASLC/ATS/ERS classification for 
pulmonary adenocarcinomas. Eur Respir J. 2012; 
40(5): 1221-7. DOI: 10.1183/09031936.00219211 
9. Warth A, Cortis J, Fink L, et al. Training increases 
concordance in classifying pulmonary 
adenocarcinomas according to the novel 
IASLC/ATS/ERS classification. Virchows Arch. 
2012; 461(2): 185-93. DOI: 10.1007/s00428-012-
1263-6           
10. Barletta JA, Yeap BY, Chirieac LR. Prognostic 
significance of grading in lung adenocarcinoma. 
Cancer. 2010; 116(3): 659-69. DOI: 
10.1002/cncr.24831    
11. Russell PA, Wainer Z, Wright GM, et al. Does lung 
adenocarcinoma subtype predict patient survival? A 
clinicopathologic study based on the new 
International Association for the Study of Lung 
Cancer/American Thoracic Society/European 
Respiratory Society international multidisciplinary 
lung adenocarcinoma classification. J Thorac 
Oncol. 2011; 6(9): 1496-504.  
DOI: 10.1097/JTO.0b013e318221f701   
12. Aida S, Shimazaki H, Sato K, et al. Prognostic 
analysis of pulmonary adenocarcinoma 
subclassification with special consideration of 




Histopathology. 2004; 45(5): 468-76. DOI: 
10.1111/j.1365-2559.2004.01946.x 
13. Yokose T, Suzuki K, Nagai K, et al. Favorable and 
unfavorable morphological prognostic factors in 
peripheral adenocarcinoma of the lung 3 cm or less 
in diameter. Lung Cancer. 2000; 29(3): 179-88. 
14. Yoshizawa A, Motoi N, Riely GJ, et al. Impact of 
proposed IASLC/ATS/ERS classification of lung 
adenocarcinoma: Prognostic subgroups and 
implications for further revision of staging based on 
analysis of 514 stage I cases. Mod Pathol. 2011; 
24(5): 653-64. DOI: 10.1038/modpathol.2010.232 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
